Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    An NIH grant/contract note for 2017 was added, and the page revision was updated from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-29T19:31:49.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    37 days ago
    Change Detected
    Summary
    The page revision was bumped from v3.6.4 to v3.6.5, signaling a minor version update to the page. It does not change the substantive study details or visible information.
    Difference
    0.1%
    Check dated 2026-08-08T18:23:31.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3, indicating a software version update for the site. This update does not change the displayed trial information or how users interact with the page.
    Difference
    0.1%
    Check dated 2026-07-25T08:46:52.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    Revision updated from v3.6.2 to v3.6.3 on the page, indicating a software deployment update.
    Difference
    0.1%
    Check dated 2026-07-03T21:53:24.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.0 to v3.6.2 on the page. This minor version update does not change any study information or user-facing content.
    Difference
    0.1%
    Check dated 2026-06-26T23:29:10.000Z thumbnail image
  9. Check
    94 days ago
    Change Detected
    Summary
    Investigator attribution was split into a standalone name entry and new metadata lines (Last verified, Last known status). The page also introduces new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a standardized label for Intervention/Treatment.
    Difference
    2%
    Check dated 2026-06-12T16:50:14.000Z thumbnail image

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.